Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Mesothelioma
- Focus Pharmacodynamics
- 02 Jun 2016 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
- 02 Jun 2016 Planned primary completion date changed from 1 Feb 2018 to 1 May 2018.
- 02 Jun 2016 Status changed from not yet recruiting to recruiting.